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Preclinical development of an oral anti-Wolbachia 
macrolide drug for the treatment of lymphatic filariasis 
and onchocerciasis
Mark J. Taylor1, Thomas W. von Geldern2,3, Louise Ford1, Marc P. Hübner4, Kennan Marsh2, 
Kelly L. Johnston1, Hanna T. Sjoberg1, Sabine Specht4, Nicolas Pionnier1, Hayley E. Tyrer1, 
Rachel H. Clare1, Darren A. N. Cook1, Emma Murphy1, Andrew Steven1, John Archer1, 
Dominique Bloemker4, Franziska Lenz4, Marianne Koschel4, Alexandra Ehrens4, Haelly M. Metuge5,6, 
Valerinne C. Chunda5,6, Patrick W. Ndongmo Chounna5,6, Abdel J. Njouendou5,6, 
Fanny F. Fombad5,6, Robert Carr2, Howard E. Morton2, Ghaith Aljayyoussi1, Achim Hoerauf4, 
Samuel Wanji5,6, Dale J. Kempf2, Joseph D. Turner1, Stephen A. Ward1*
There is an urgent global need for a safe macrofilaricide drug to accelerate elimination of the neglected tropical 
diseases onchocerciasis and lymphatic filariasis. From an anti-infective compound library, the macrolide veteri-
nary antibiotic, tylosin A, was identified as a hit against Wolbachia. This bacterial endosymbiont is required for 
filarial worm viability and fertility and is a validated target for macrofilaricidal drugs. Medicinal chemistry was 
undertaken to develop tylosin A analogs with improved oral bioavailability. Two analogs, A-1535469 and 
A-1574083, were selected. Their efficacy was tested against the gold-standard second-generation tetracycline 
antibiotics, doxycycline and minocycline, in mouse and gerbil infection models of lymphatic filariasis (Brugia 
malayi and Litomosoides sigmodontis) and onchocerciasis (Onchocerca ochengi). A 1- or 2-week course of oral 
A-1535469 or A-1574083 provided >90% Wolbachia depletion from nematodes in infected animals, resulting in a 
block in embryogenesis and depletion of microfilarial worm loads. The two analogs delivered comparative or 
superior efficacy compared to a 3- to 4-week course of doxycycline or minocycline. A-1574083 (now called ABBV-
4083) was selected for further preclinical testing. Cardiovascular studies in dogs and toxicology studies in rats and 
dogs revealed no adverse effects at doses (50 mg/kg) that achieved plasma concentrations >10-fold above the 
efficacious concentration. A-1574083 (ABBV-4083) shows potential as an anti-Wolbachia macrolide with an efficacy, 
pharmacology, and safety profile that is compatible with a short-term oral drug course for treating lymphatic fil-
ariasis and onchocerciasis.
INTRODUCTION
Control programs for neglected tropical diseases caused by the filar-
ial parasites responsible for lymphatic filariasis and onchocerciasis 
have been operating for more than 40 years, with notable successes 
in the Americas and West Africa (1). Nevertheless, it is recognized 
that the transition from control to elimination will require alterna-
tive strategies and approaches (1, 2). In particular, global efforts to 
eliminate filarial diseases are hampered by the lack of a drug that 
can kill the adult nematode, relying instead on multiple rounds of 
mass drug administration with agents that target the transmission of 
microfilariae (the larval stages found in either blood or skin) (2, 3). 
The success of existing strategies in Central Africa is also impeded 
by the risk of severe adverse events in areas coendemic for infection 
with the related filarial nematode, Loa loa (2, 3).
The anti-Wolbachia (A∙WOL) consortium was formed to exploit 
a unique aspect of filarial parasite biology, which is their reliance on 
the presence of the bacterial endosymbiont Wolbachia for fertility 
and viability (4). Clinical studies using doxycycline have demonstrated 
that depletion of Wolbachia within filarial parasites arrests embryo-
genesis, prevents larval development, clears microfilarial stages from 
blood or skin, mediates transmission blockade and prevention of on-
chocerciasis pathology, and leads to a slow but innocuous death of 
adult parasites over 12 to 24 months (3, 5, 6). However, doxycycline is 
contraindicated in children and pregnant women and requires 4 to 
6 weeks of daily therapy to sufficiently deplete the Wolbachia popula-
tion to produce a macrofilaricidal effect. Therefore, agents with more 
favorable safety profiles and shorter duration of therapy are needed 
(4). To date, more than 2 million compounds have been screened for 
anti-Wolbachia activity in an insect cell line (7, 8).
RESULTS
Here, we screened an anti-infective compound library and identified the 
16-membered macrolide antibiotic tylosin A (Fig. 1) as a potent hit. This 
drug had an in vitro effective concentration providing 50% effect (EC50) 
of 30 nM against Wolbachia in the C6/36 (wAlbB)-infected insect cell 
line and 66 nM against Wolbachia in microfilariae of Brugia malayi 
(Table 1). Tylosin A, the principal component of a widely used veteri-
nary antibiotic produced by fermentation, was the only macrolide 
in the screening set to demonstrate anti-Wolbachia activity; other com-
mercially available 16-membered macrolides were devoid of activity (8). 
We tested the efficacy of tylosin A in two mouse models of lymphatic 
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filariasis (9, 10). In the first model, interleukin-4 receptor alpha- 
deficient (IL-4R−/−) BALB/c immunodeficient mice were infected 
with third-stage larvae (L3) of B. malayi, a human lymphatic filarial 
pathogen (9). In the second model, BALB/c mice were infected with 
L3 larvae of Litomosoides sigmodontis, which naturally infects cotton 
rats (10). In the B. malayi model, infectious stage larvae were isolated 
from mosquitoes and, after inoculation into the immunodeficient mice, 
were allowed to develop into adults that produced microfilarial stages 
contained within the peritoneal cavity of the host animals. In the 
L. sigmodontis natural infection model, larvae migrated to the pleu-
ral cavity of mice via the lymphatics, heart, and lungs and became 
microfilariae-producing adults. Worm infections were established by 
exposing BALB/c mice to blood feeding by L. sigmodontis–infected 
Ornithonyssus bacoti mites. In both animal models, drugs were de-
livered orally or parenterally (via intraperitoneal injection) immedi-
ately after infection, thus targeting larval developmental stages. In 
initial screening, the impact on the Wolbachia load was assessed 
at either 2 (B. malayi) or 5 weeks (L. sigmodontis) after infection, 
corresponding to the mid-L4 larval stage or early adult stage, respec-
tively. In both animal models, anti-Wolbachia efficacy was demon-
strated when tylosin A was delivered parenterally but not orally (Fig. 2A 
and fig. S1). Pharmacokinetic (PK) studies in mice confirmed that 
the lack of anti-Wolbachia activity of oral tylosin A was the result of 
poor oral bioavailability (table S1). Worm burdens in the mice were 
not affected by either tylosin analogs or doxycycline after 2 weeks of 
treatment (table S2).
We hypothesized that low intestinal permeability limited the oral 
bioavailability of tylosin A due to its extensive network of hydrogen- 
bond donors, specifically the five free hydroxyl groups in the molecule. 
To address this challenge, we focused medicinal chemistry efforts pri-
marily on the derivatization of these hydroxyl moieties, recognizing 
that such modifications might compromise activity against Wolbachia. 
From studies on ~150 new tylosin analog macrofilaricide (TylAMac) 
compounds, we determined that derivatives of the 4″-OH (on the 
mycarose sugar) provided a dual benefit of improved bioavailability 
and enhanced potency against Wolbachia. Table 1 shows the in vitro 
anti- Wolbachia potency (EC50 values in insect cells and cultured 
B. malayi microfilariae) for two extensively characterized semisyn-
thetic lead compounds (A-1535469 and A-1574083) compared to 
tylosin A and doxycycline. The increased potency exhibited by these 
TylAMac analogs appeared to be specific for Wolbachia. Their spec-
trum of activity across a panel of other common bacterial species was 
similar to that of tylosin A (table S3) and erythromycin. The efficacy 
of A-1535469 and A-1574083 against B. malayi developing larvae 
(L3 to L4 stage) in susceptible IL-4R−/− BALB/c immunodeficient 
mice was compared to that of tylosin A and a human equivalent 
dose of doxycycline (fig. S2) (9, 11). Fourteen-day oral dosing with 
A-1535469 at ≥25 mg/kg delivered superior efficacy versus doxycycline 
(50 mg/kg) [Kruskal-Wallis one-way analysis of variance (ANOVA) 
statistic = 90.7, P < 0.0001; Fig. 2A]. Fourteen-day oral dosing with 
A-1535469 resulted in an anti-Wolbachia efficacy equivalent to that 
achieved with 14 daily injections of tylosin A (50 mg/kg) (98.6% ver-
sus >99.9%, respectively; Fig. 2A). When halving the dose duration 
to 7 days, A-1535469 (≥25 mg/kg) provided superior activity versus 
14 days of oral doxycycline (A-1535469 >99.7% median reduction in 
Wolbachia versus 98.1% for doxycycline; Fig. 2A). Wolbachia depletion 
Fig. 1. Synthesis of tylosin A analogs. Tylosin A (the parent compound 1) was first protected on the reactive 2′-hydroxyl group through acetylation to give compound 2. 
Selective activation of the mycarosyl sugar was accomplished through formation of a cyclic tin complex; this was reacted with diethylcarbamoyl chloride to give com-
pound 3 [R = –C(O)NEt2] or with 4-fluorobenzyl chloride to give compound 3 [R = –Bn(4-F)]. Warming in methanol liberated the 2′-ester protective group to provide 
A-1535469 [compound 4, R = –C(O)NEt2] or A-1574083 [compound 4, R = –Bn(4-F)]. Both A-1535469 and A-1574083 were tested for efficacy against the bacterial endo-
symbiont Wolbachia both in insect cells and microfilariae in vitro and in worms infecting mice and gerbils in vivo.
Table 1. Anti-Wolbachia activity of tylosin A analogs in vitro.  
Anti-Wolbachia activity EC50 (nM)
Insect cells B. malayi microfilariae
A-1535469 1.3 1.6
A-1574083 0.02 0.7
Tylosin A 30 66
Doxycycline 20 166
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Fig. 2. In vivo efficacy of two oral tylosin A analogs against Wolbachia in several animal models of nematode infection. The efficacy of two tylosin A analogs (A-1535469 
and A-1574083) against Wolbachia in mice infected with B. malayi, L. sigmodontis, or O. ochengi is shown. Efficacy of the two drugs was tested against Wolbachia in (A) B. malayi 
L3/L4 larvae infecting IL-4R−/− BALB/c immunodeficient mice (n = 3–7) or in (B) adult female B. malayi worms infecting CCR3−/− BALB/c immunodeficient mice (n = 4–5). 
Tylosin A (red) was given orally or intraperitoneally (ip) where indicated; the tylosin A analogs A-1535469 (yellow) and A-1574083 (blue) were given orally. Efficacy was 
compared against (A) doxycycline (DOX, open symbols) or (B) minocycline (MIN, open symbols). All treatments were administered once daily for 14 days (squares) or 7 days 
(triangles) at the indicated doses except for minocycline (B), which was administered for 28 days (circles) twice daily (mpk, mg drug per kg body weight). (C and D) The 
anti-Wolbachia efficacy of orally administered A-1574083 (blue) was tested in gerbils infected with adult female B. malayi [C (n = 4–7)] or adult female L. sigmodontis [D (n = 5–6)] 
worms. Efficacy was compared against that for doxycycline. All treatments were administered once daily for 21 days (hexagons) or 14 days (squares) at the indicated doses 
except (D) doxycycline, which was administered for 14 days twice daily. (E and F) Anti-Wolbachia efficacy of oral A-1535469 (yellow) or A-1574083 (blue) was tested against 
male adult O. ochengi in SCID immunodeficient mice [E (n = 4–8)] or gerbils [F (n = 4–5)]. Efficacy was compared to that for minocycline (E, open symbols) or doxycycline 
(F, open symbols). All treatments were administered once daily for either 21 days (hexagons), 14 days (squares), or 7 days (triangles) at the indicated doses except minocycline 
(E), which was administered for 28 days twice daily. Data on Wolbachia depletion are presented as Wolbachia surface protein (wsp) gene copy number (A and B), Wolbachia 
wsp/nematode glutathione-S-transferase (gst) gene copy number ratio (C, E, and F), or Wolbachia filamenting temperature-sensitive mutant-z (ftsz)/nematode actin (act) 
gene copy number ratio (D). Data are presented per worm, with 5 to 15 worms per group derived from four to six animals per group and normalized to the median vehicle 
control Wolbachia gene copy number or ratio. Magenta lines indicate the median value for vehicle control, and blue lines indicate 90% efficacy. Short horizontal black 
lines above plots indicate median measurements. Data points are for single experiments (B to D and F) or else pooled from two individual experiments (A, C, and E). Signifi-
cant differences, ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05 (Mann-Whitney or Kruskal-Wallis with Dunn’s tests for intergroup variation).
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after 7 days of oral dosing of infected immunodeficient mice with 
A-1574083 at ≥25 mg/kg was comparable to that after 14 days of dox-
ycycline treatment (A-1574083 >97% versus 98.1% median reduction 
in Wolbachia for doxycycline; Fig. 2A). Larval worm burdens were 
unaffected by any of the treatments (table S2).
Our aim was to develop an anti-Wolbachia compound that could 
be given as an oral short-course treatment effective against adult lym-
 phatic worms and Onchocera filarial worms. To that end, A-1535469 
and A-1574083 were tested in several in vivo mouse and gerbil models 
infected with adult-stage B. malayi or L. sigmodontis or implanted 
with male Onchocerca ochengi (Fig. 2, B and F, and fig. S2) (9-11). 
Both C-C chemokine receptor 3 (CCR3)– 
deficient (CCR3−/−) mice or severe com-
bined immunodeficient (SCID) mice 
were used, in which chronic infections of 
B. malayi adult worms producing micro-
filariae could be maintained (9, 11).
Gerbil models were used in addition 
to mouse models for testing A-1574083 
due to improved PKs in gerbils, which 
enabled higher in vivo plasma concen-
trations of drug to be obtained. When 
targeting prefecund B. malayi adult 
worms in vivo with A-1535469 in the 
CCR3−/− BALB/c mouse infection model 
(Fig. 2B), all oral treatments given daily 
(50 to 250 mg/kg) for 14 days provided 
efficacy that was comparable to a 4-week 
bioequivalent human dose of minocy-
cline (12) at 25 mg/kg given twice daily. 
Minocycline was used as a more potent 
tetracycline antibiotic because it was 
shown to be superior to doxycycline 
in depeleting Wolbachia from female 
Onchocerca volvulus in a pilot clinical 
study of infected individuals (13). Treat-
ment of CCR3−/− immunodeficient mice 
with A-1535469 (250 mg/kg) for 7 days 
provided 98.3% median reduction in 
Wolbachia in adult female B. malayi 
worms (compared to 91.4% after 28 days 
of minocycline treatment). This thresh-
old indicated the potential for curative 
efficacy for lymphatic filariasis in humans 
(14, 15). Treatment with A-1574083 
(50 mg/kg) for 14 days in a gerbil model 
of B. malayi infection showed targeting 
of the fecund stage of B. malayi worms. 
This treatment regimen resulted in a 99.6% 
median reduction in Wolbachia and was 
superior to a 21-day (100 mg/kg) dose of 
doxycycline (98.5% median reduction 
with doxycycline; Fig. 2C). Administra-
tion of a 14-day reduced (10 mg/kg) dose 
of A-1574083 also resulted in >99% de-
pletion of Wolbachia that was comparable 
to that of a 21-day doxycycline regimen 
(Fig. 2C). In a parallel study of L. sig-
modontis infection in a gerbil model, 
dosing was delayed until after the onset of patency (i.e., when circu-
lating microfilariae were detectable in peripheral blood). A dose 
of A-1574083 (100  mg/kg) given for 14  days resulted in 99.7% 
mean reduction in Wolbachia compared to 0% median reduction 
in Wolbachia after doxycycline treatment (Fig. 2D). The drug treat-
ments did not affect adult worm burdens in these two gerbil models 
(tables S4 to S6).
Because of the high efficacy achieved in mouse and gerbil models of 
lymphatic filariasis infection, we next investigated whether A-1535469 
and A-1574083 showed anti-Wolbachia activity in mouse and gerbil 
models of Onchocerca infection. Preclinical models of onchocerciasis 
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Fig. 3. In vivo efficacy of oral tylosin A ana-
logs against B. malayi or L. sigmodontis mi-
crofilariae and worm embryonic stages. The 
embryostatic efficacy of two tylosin A analogs 
(A-1535469 and A-1574083), resulting in block-
ade of microfilarial production and subsequent 
depletion of mature microfilariae from mice or 
gerbils infected with B. malayi or L. sigmodontis, 
is shown. (A) The number of B. malayi micro-
filariae in the peritoneal cavity recovered by la-
vage of nematode-infected immunodeficient 
SCID mice 24 weeks after administration of oral 
A-1535469 (yellow squares) is shown (n = 7–9). 
Results are compared to vehicle control (gray 
circles) or control antibiotic treatment with 
minocycline (open circles). Drugs were admin-
istered at indicated doses once daily for 14 days (A-1535469, yellow squares) or twice daily for 28 days (minocycline, 
open circles). (B) The number of B. malayi microfilariae recovered by lavage from the peritoneal cavity of infected 
gerbils 6 and 12 weeks after oral administration of A-1574083 (blue squares) once daily for 14 days at the indicated 
dose compared with vehicle control (gray circles) is shown. Data plotted (A and B) are total yields of peritoneal 
microfilariae per lavage of individual animals (groups of 6 to 9). Short horizontal black lines over plots are median yields 
of microfilariae. (C) The number of L. sigmodontis microfilariae in the peripheral blood of infected gerbils 1 week be-
fore treatment and 2 to 16 weeks after treatment with oral A-1574083 (blue squares) compared to vehicle control 
(gray circles) or the antibiotic control doxycycline (open squares) is shown. Drugs were administered at indicated 
doses once daily (A-1574083, blue squares) or twice daily (doxycycline, open squares) for 14 days. Data and error bars 
are mean microfilariae counts per ml of blood ±1 SE, derived from groups of six gerbils. (D) The number of worm 
intrauterine embryonic stages (morulae, coiled microfilariae, and stretched microfilariae) 16 weeks after oral A-1574083 
treatment (blue squares) compared to vehicle control (gray circles) or doxycycline control (open squares) is shown. 
Drugs were administered at indicated doses once daily (A-1574083, blue squares) or twice daily (doxycycline, open 
squares) for 14 days. Data plotted are the total number of released embryonic stages per individual adult female worm 
(groups of 7 to 11). Short horizontal lines over plots are median yields of microfilariae. Addition of +1 to all continuous 
variables was undertaken to visualize zero data plotted on a log scale. Significant differences, ****P < 0.0001, 
***P < 0.001, **P < 0.01, and *P < 0.05, were determined by Kruskal-Wallis with Dunn’s tests for intergroup Wolbachia 
variation (A), Mann-Whitney tests (B), or one-way ANOVA with Dunnett’s tests for intergroup variation after logarithm 
to the base 10 transformation (C and D).
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were generated by implanting adult male O. ochengi parasites isolated 
from naturally infected cattle (11, 16) into immunodeficient mice or 
outbred gerbils. Both A-1535469 (250 mg/kg) and A-1574083 
(75 mg/kg) given for 14 days mediated a 99.4 and 98.8% median 
reduction in Wolbachia, respectively, in immunodeficient mice im-
planted with Onchocerca (Fig. 2E). This was comparable to the efficacy 
of a 28-day course of minocycline (25 mg/kg), resulting in a 99.2% 
median reduction in Wolbachia (Fig. 2E). When Onchocerca-infected 
gerbils were dosed at 150 mg/kg of A-1574083 for 7 days, there was 
a 95.7% depletion in Wolbachia compared to 98.0% for doxycycline 
(Fig. 2F). Onchocerca male worm burdens were not affected by drug 
treatments (tables S7 and S8).
We next assessed whether depletion of Wolbachia by A-1535469 
or A-1574083 also resulted in reduced production of microfilariae 
in B. malayi and L. sigmodontis infection models (Fig. 3). Dosing 
experiments were undertaken in immunodeficient mice or gerbils 
infected with B. malayi or L. sigmodontis, with washout periods of 
up to 22 weeks after dosing to measure the impact of these two tylosin 
A analogs on parasite fecundity (fig. S2). In immunodeficient mice 
with fecund B. malayi infection, released microfilariae accrued in 
the peritoneal cavity and typically reached a steady-state burden of 
≥105 per animal. Twenty-four weeks after a 14-day dosing regimen 
with A-1535469 (250 mg/kg), there was no difference in adult worm 
burden compared with vehicle control (table S9). However, 24 weeks 
after treatment, four of nine mice showed no peritoneal microfilariae 
with a median microfilarial burden in the A-1535469–treated group 
of 0.00032 × 105 (range, 0 to 0.11 × 105; Fig. 3A). This was equiva-
lent to a >99.99% reduction in microfilarial burden for A-1535469 
treatment compared to vehicle control (median microfilarial burden 
of 5.7 × 105; range, 1.5 to 9.4 × 105; Fig. 3A). Microfilarial depletion 
after a 14-day treatment with A-1535469 was greater than that 
achieved with a 28-day course of minocycline (25 mg/kg) twice daily. 
Minocycline treatment resulted in an 83% reduction in peritoneal 
microfilariae 24 weeks after treatment initiation with a median micro-
filarial burden of 0.96 × 105 (range, 0.008 to 4.4 × 105; Fig. 3A).
The effects of a 14-day treatment with A-1574083 (150 mg/kg) 
on microfilarial production were examined in gerbils with a fecund 
B. malayi peritoneal infection. We performed peritoneal lavage at 6 
and 12 weeks after treatment to harvest the microfilariae accrued 
before, during, and after drug treatment. At 6 weeks after treatment, 
all gerbils showed peritoneal microfilariae (Fig. 3B), and the median 
peritoneal microfilarial burden (4.2 × 105) was similar to that of 
animals given vehicle control (10.9 × 105). After a further 6 weeks 
(12 weeks after treatment), peritoneal microfilarial burdens were sus-
tained in the vehicle group with six of six gerbils, showing a median 
microfilarial burden of 0.15 × 105. No microfilarial burden was de-
tected in lavages of infected gerbils dosed with A-1574083 (Fig. 3B).
Patent L. sigmodontis infection in gerbils seeds the blood with 
microfilariae, hence establishing persistent microfilaraemia akin to 
that of patients infected with lymphatic filariasis. We undertook a 
longitudinal assessment of L. sigmodontis microfilaraemia after dosing 
with A-1574083 (100 mg/kg once daily) or doxycycline (40 mg/kg 
twice daily) for 14 days. Baseline microfilaraemias were similar 
between gerbils treated with A-1574083, doxycycline, or untreated 
controls (Fig. 3C). At 10 weeks after treatment, L. sigmodontis 
microfilaraemia declined in gerbils treated with A-1574083 or doxy-
cycline compared to untreated animals. However, in A-1574083–
treated gerbils, the microfilaraemia continued to decline from 11 to 
16 weeks after treatment, and the gerbils showed no microfilariae in 
the blood at week 15 after dosing (Fig. 3C). The effect of A-1574083 
on circulating microfilariae was superior to that of doxycycline over 
the same time period (Fig. 3C) and correlated with the improved clear-
ance of Wolbachia by A-1574083 (Fig. 2D). At 16 weeks after dosing, 
a similar number of adult L. sigmodontis worms were retrieved across 
all groups (table S6). Microscopic evaluation after homogenization 
of remaining L. sigmodontis female worms confirmed a decline in 
the number of intrauterine embryonic stages (morulae, coiled micro-
filariae, and stretched microfilariae) after 14 days of A-1574083 
treatment compared to untreated controls (Fig. 3D).
Table 2. Plasma concentrations of tylosin A analogs after single oral 
dosing in mice and gerbils.  
Compound Species Dose (mg/kg) AUC0-inf (ng∙hr/
ml) (SEM)
A-1535469 BALB/c mice 30 7800 (1620)
100 36100 (2910)
A-1574083 BALB/c mice 25 17.9 (0.85)
50 271 (23.7)
75 2153 (1089)
Gerbils 8.92 60.9 (15.5)
47 3646 (619)
82.2 5169 (478)
149 9200 (276)
Table 3. Activity of A-1574083 (ABBV-4083) in preclinical safety 
assays.  
Assay Result
Chloride channel (GABA-gated) 
(antagonist radioligand) Ki 7.5 M
NK1 (human) (agonist radioligand) Ki 0.1 M
NK1(human) (antagonist effect) KB 0.46 M
Motilin (human) (agonist 
radioligand) IC50 > 100 M
ERG (human) (QPatch, human 
embryonic kidney–293 cells) IC50 > 28 M
MiniAmes test (Salmonella TA98/
TA100) Negative
In vitro micronucleus test (V79 
hamster) Negative
Anesthetized dog cardiovascular 
effects (intravenous infusion)
Minimal effects* at 12.4 g/ml
28-day toxicology study in 
Sprague-Dawley rats
NOAEL: 300 mg/kg per day
Plasma AUCss: 7.4 g∙hour/ml
28-day toxicology study in beagle 
dogs
NOAEL: 15 mg/kg per day
Plasma AUCss: 3.0 g∙hour/ml
*Monitored characteristics: mean arterial pressure, heart rate, systemic 
vascular resistance, cardiac output, cardiac contractility, QT interval 
corrected using Van de Water formula, and interval from P to R on 
electrocardiogram.
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Table 2 shows the plasma concentrations [area under the curve 
(AUC)] for A-1535469 and A-1574083 after a single oral dose in un-
infected BALB/c mice and gerbils. Although A-1574083 showed poor 
bioavailability in this strain of mouse, the efficacy of this drug against 
Wolbachia in vivo was similar to that of A-1535469. Combining data 
from PK and efficacy studies, we created an exploratory PK/PD (phar-
macodynamic) model (fig. S3). We analyzed plasma concentrations 
of drug in both larval and adult B. malayi–infected animals dosed 
for 14 days with A-1574083 or A-1535469. We determined that the 
maintenance of unbound plasma concentrations of drug above the 
in vitro EC50 (defined using Wolbachia in insect cells) for more than 
12 hours/day produced a >90% decline in Wolbachia from nema-
todes in infected mice (fig. S3).
After extensive comparison of the two lead compounds, A-1574083 
(now called ABBV-4083) was selected for evaluation as a preclinical 
drug candidate on the basis of its greater potency together with ac-
ceptable PKs and safety in mouse and gerbil worm infection models. 
More limited development of A-1535469 has been undertaken as a 
backup strategy. A-1574083 demonstrated interactions with only 2 of 
77 mammalian receptors, ion channels, enzymes, and transporter 
assays [neurokinin NK1 receptor and the -aminobutyric acid 
(GABA)–gated chloride channel at a concentration of 10 M] as-
sessed in vitro (Table 3). The inhibitory concentration providing 
50% inhibition (IC50) for the human ether-a-go-go-related gene en-
coding a potassium channel (associated with cardiovascular toxici-
ties) was >28 M. A-1574083 exhibited no binding at 100 M to the 
gastrointestinal motilin receptor, an off-target receptor for some 
macrolide antibiotics (Table 3) (17). A-1574083 tested negative in the 
Mini- Ames mutation assay and in the micronucleus assay (Table 3). 
Cardiovascular studies completed in dogs and 28-day toxicology 
studies completed in rats and dogs showed that A-1574083 plasma 
concentrations at the no adverse effect levels (NOAELs) were above 
the plasma concentrations obtained with efficacious doses in mouse 
and gerbil infection models (Table 3).
The L. loa filarial parasite lacks Wolbachia, precluding an anti- 
Wolbachia–based mechanism of action against this parasitic worm. 
To investigate potential off- target effects, we undertook in vitro 
counter screening against L. loa microfilariae using continuous ex-
posure to 0.032 to 100 M A-1574083. No effect on the motility of 
L. loa microfilariae was observed until concentrations exceeded 
4 M with an estimated IC50 of 23.3 M (fig. S4). The IC50 for L. loa 
motility inhibition was >100-fold above the estimated peak unbound 
plasma concentration of A-1574083 (unbound Cmax = 0.18 M) at 
the efficacious dose (50 mg/kg) in gerbils. This indicated a wide sepa-
ration in the concentration of A-1574083 needed for anti- Wolbachia 
activity and direct microfilaricidal effects on L. loa microfilariae.
DISCUSSION
The discovery and development of anti-Wolbachia tylosin analog 
macrofilaricides yielded the candidate molecule A-1574083 (ABBV-
4083). A-1574083 demonstrated potent anti-Wolbachia activity in 
animal models, including nematode-infected immunodeficient mice 
and gerbils. This activity was comparable or superior to “gold-standard” 
second-generation tetracycline antibiotics. A-1574083 showed robust 
anti-Wolbachia activity with a short treatment time frame of 7 to 
14 days compared to second-generation tetracycline antibiotics with 
a treatment time frame of 21 to 28 days. This suggests that the 
A-1574083 analog may provide clinical benefits with a short dosing 
regimen. A-1574083 also displayed a promising preclinical safety 
profile.
Curative activity after effective Wolbachia depletion is evident 
18 months after treatment in patients infected with nematodes (13, 18). 
A more immediate manifestation of Wolbachia depletion from adult 
female filarial reproductive tissue, observed both in rodent models and 
in clinical trials (13, 18), is the arrest of worm embryogenesis 2 to 
6 months after treatment. This subsequently leads to a slow waning of 
mature microfilariae from the blood or skin and ultimately clearance 
of microfilarial infection in lymphatic filariasis and onchocerciasis 
within a period of 12 to 22 months after treatment (19-22). This im-
portant effect of anti-Wolbachia treatment mediates transmission- 
blocking efficacy and prevents further skin and eye disease attributable 
to O. volvulus microfilariae infection. Here, we demonstrate the anti- 
Wolbachia activity of A-1574083 and the sustained disruptive effects 
of this treatment on adult filarial embryogenesis. This led to a blockade 
in the release of microfilariae and gradual complete clearance of circu-
lating microfilariae in B. malayi and L. sigmodontis rodent models of 
worm infection.
The risk of potentially life-threatening serious adverse events in 
patients with onchocerciasis who are coinfected with the related fi-
larial worm L. loa (23) is a major issue hindering adherence to the 
rapid-acting microfilaricidal drug, ivermectin. New macrofilarici-
dal agents need to be safe to administer to coinfected patients at risk 
of severe adverse reactions to ivermectin. On the basis of its anti- 
Wolbachia activity, A-1574083 was predicted to be safe for treating 
individuals coinfected with Onchocerca and L. loa, with initial in vitro 
testing indicating no direct L. loa cidality at concentrations far ex-
ceeding those required for depletion of Wolbachia.
Our study has several limitations. Although robust Wolbachia 
depletion was demonstrated for several nematode species including 
Onchocerca, the rodent models of filarial infection harbor adult worms 
in sites (e.g., the peritoneal cavity) that are highly accessible to drug 
entry from the blood. In contrast, in human infection, O. volvulus 
adults are present in subcutaneous and deep-tissue nodules. Although 
these nodules are well vascularized, drug uptake into O. volvulus nod-
ules may not be as efficient as into the adult worms in rodent models. 
The dependence of efficacy on drug dose versus duration of dosing is 
also not well defined. Although higher doses offer the potential for 
shorter dose duration, the detailed relationship between drug dose and 
dose duration is not well understood. This crucial relationship needs 
to be elucidated if this drug regimen is to satisfy specific target product 
profiles for point-of-care treatment and mass administration under 
difficult field conditions.
MATERIAL AND METHODS
Study design
The research objective of our study was to develop a short-course oral 
antibiotic that was effective against nematodes infected with the bac-
terial endosymbiont Wolbachia, which could be advanced into clinical 
testing as a new treatment for lymphatic filariasis and onchocerciasis. 
Phenotypic in vitro screening of a small-molecule library against in-
sect Wolbachia was done in a blinded manner and subsequently de-
coded to identify a potent “hit” antibiotic, tylosin A. Confirmatory 
phenotypic screening against nematode Wolbachia, medicinal chem-
istry, iterative in vitro screening, and rodent (mouse and gerbil) PKs 
of tylosin A oral analogs were performed in a nonblinded manner. 
Two tylosin A analogs with improved in vitro potency and acceptable 
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rodent PK characteristics were advanced into a series of rodent efficacy 
studies. Rodents were randomized into drug groups. Scientists were 
involved in drug treatments, and parasitological and molecular read-
outs were blinded to the treatment group, with the exception of the 
L. sigmodontis drug screens, which were done in a nonblinded manner. 
Details of animal age and sex are provided below. Group numbers 
of rodents used in in vivo experiments are provided below and in the 
figure legends.
Synthesis of tylosin A analogs
A-1535469 and A-1574083 were synthesized from tylosin A using a 
three-step procedure (Fig. 1). Briefly, the 2′-OH (mycaminose) of 
tylosin was protected (acetic anhydride) as the corresponding acetate, 
followed by selective activation of the 3″- and 4″-OH groups through 
the formation of a cyclic tin complex (using dibutyltin oxide) and then 
by derivatization of the 4″-OH (mycarose) with either diethylcarbam-
oyl chloride or p-fluorobenzyl bromide/Caesium fluoride. Subsequent 
deprotection of the 2′-acetate (refluxing methanol) provided A-1535469 
or A-1574083.
In vitro cell-based screen for anti-Wolbachia activity
Compounds were screened for anti-Wolbachia activity in vitro 
in the A·WOL-validated Wolbachia-infected Aedes albopictus 
(C6/36 wAlbB) 7-day cell-based screen. This screen used a 384-well 
format assay with high-content imaging (Operetta), as previously 
described (7).
Animals
Inbred male SCID CB.17 (BALB/c congenic) mice were purchased 
from Charles River Laboratories, UK. Inbred IL-4R−/− or CCR3−/− 
BALB/c breeding pairs were purchased from Jackson laboratory, USA. 
Outbred Meriones unguiculatus gerbil breeding pairs were purchased 
from Charles River Laboratories, Europe. Rodents were maintained 
and bred under specific pathogen–free conditions at the University of 
Liverpool Biological Services Unit or in individually ventilated cages 
at the Research Foundation for Tropical Medicine and The Environ-
ment, Buea, Cameroon. All experiments were approved by the ethical 
committees of the University of Liverpool and Liverpool School of 
Tropical Medicine or the University of Buea Animal Ethics Review 
Board, Cameroon. Studies were conducted in accordance with Home 
Office legislation (UK-based studies), and matching welfare standards 
were applied in Cameroon.
Experiments with L. sigmodontis were performed at the Institute 
for Medical Microbiology, Immunology and Parasitology, University 
Hospital Bonn in accordance with the European Union’s animal wel-
fare guidelines, and all protocols were approved by the Landesamt für 
Natur, Umwelt und Verbraucherschutz, Cologne, Germany (AZ 84-
02.04.2015.A507 and AZ 84-02.04.2012.A140).
Female M. unguiculatus gerbils were obtained from JANVIER 
LABS (Saint-Berthevin, France) and housed at the animal facility of 
the Institute for Medical Microbiology, Immunology and Parasitology 
in individually ventilated cages on a 12-hour light/12-hour dark cycle 
with food and water ad libitum.
For PK experiments, male Mongolian gerbils were purchased 
from Zhejiang Academy of Medical Science (China) and were in-
dividually housed in a climate controlled room, with free access to 
food and water in the animal facilities of WuXi AppTec, Shanghai, 
China. Female Balb/c mice were purchased from Charles River Lab-
oratories (Wilmington, MA) and were maintained in the Associa-
tion for Assessment and Accreditation of Laboratory Animal Care 
International– approved animal facilities of AbbVie Inc., North 
Chicago, IL. All experiments were conducted in accordance with 
the guidelines approved by the internal Institutional Animal Care 
and Use Committee.
Screening of anti-Wolbachia activity in nematodes in vitro
Compounds were further scrutinized for anti-Wolbachia activity in 
vitro in a microfilarial assay. Microfilariae were obtained by perito-
neal lavage of gerbils (M. unguiculatus) harboring a patent infec-
tion of B. malayi as previously described (11). Microfilariae were 
purified and resuspended in complete medium consisting of RPMI 
(Invitrogen) supplemented with 10% fetal bovine serum (Fisher 
Scientific), 1% penicillin/streptomycin, and 1% amphotericin B (Life 
Technologies). Micro filariae were plated at 8000 microfilariae per 
well in a 96-well plate (100 l per well). Compounds to be tested 
[10-mm stock in 100% dimethyl sulfoxide (DMSO)] were diluted in 
complete medium, and 100 l was added to the appropriate wells 
to give a dose- response curve. Five replicates were used for each 
compound, and each plate contained doxycycline (5 M) and DMSO 
controls. The assay plates were incubated at 37°C for 6 days in 5% 
CO2, after which DNA was extracted using the QIAmp DNA Mini 
Kit (Qiagen). Quantitative polymerase chain reaction (qPCR) was 
performed to obtain the ratio of wsp to gst gene copy number, as 
previously described (11).
Screening of anti-Wolbachia activity in  
nematode-infected animals
Infectious stage B. malayi L3 larvae were propagated, as previous-
ly described (11). Male mice 6 to 12 weeks of age or male gerbils 8 
to 16 weeks of age were infected with B. malayi L3 larvae intraperi-
toneally (50 or 100 L3 larvae per mouse; 400 L3 larvae per gerbil), 
and infections were maintained for a maximum of 40 weeks. Mo-
tile B. malayi microfilariae were recovered by peritoneal lavage at 
necropsy and were enumerated by microscopy. Viable adult male 
O. ochengi nematodes were aseptically isolated from naturally para-
sitized cattle, as previously described (11). Between 10 to 20 male 
Onchocerca were surgically implanted into the peritoneal cavity of 
male SCID CB.17 mice or female gerbils, under anesthesia, as pre-
viously described (11).
For L. sigmodontis infection, 6- to 8-week-old female gerbils or 
6- to 8-week-old female Balb/c mice were exposed to O. bacoti mites 
containing the infective stage L3 larvae of L. sigmodontis, as previ-
ously described (24). The same batch of mite-containing bedding 
was used to infect all animals of one experiment. Treatment of mice 
with tylosin A analogs or antibiotics was initiated 1 day after infec-
tion, and necropsies were performed 35 days after infection. Treat-
ment of gerbils with tylosin A analogs or antibiotics started 12 weeks 
after infection, and necropsies of gerbils occurred 16 weeks after the 
start of treatment. L. sigmodontis worms were isolated from the tho-
racic cavity and peritoneum and were quantified, as previously described 
(24). For microfilarial counts in gerbils, 10 l of peripheral blood was 
taken from the saphenous vein in weekly intervals starting at 11 weeks 
after infection and diluted in 300 l of Hinkelmann solution (0.5% eosin 
Y, 0.5% phenol, and 0.185% formaldehyde in aqua dest). After cen-
trifugation at 400g for 5 min, the supernatant was discarded, and the 
pellet was resuspended and completely transferred to a microscope 
slide to quantify microfilariae using a microscope, as previously de-
scribed (25). After necropsy of gerbils, remaining intact female worms 
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were used in equal numbers for either embryograms or Wolbachia 
quantification. For embryograms, single female adult worms were 
homogenized in 20% Hinkelmann/80% phosphate- buffered saline 
(PBS), diluted 1:10 in PBS, and enumerated via microscopy. The 
analyzed embryonal stages included eggs, morulae, pretzel microfi-
lariae, and stretched microfilariae.
Treatment of infected animals with tylosin A analogs  
and antibiotics
Infected animals were randomly assigned into dose groups with n = 3 
to 7 for larval-stage testing and n = 4 to 9 for adult-stage testing. Ran-
domization was done by stratification based on ID number (B. malayi 
larval and prefecund adult infections), baseline ultrasonography esti-
mates of worm burden (B. malayi infection of SCID mice and gerbils) 
using a semi-quantifiable scoring system (26), baseline microfilariae-
mia (L. sigmodontis infection of gerbils), or order of implantation and 
source of male worms (O. ochengi implantation into SCID mice or 
gerbils).
Tylosin A (Sigma-Aldrich) or the tylosin A analogs, A-1535469 or 
A-1574083, were dissolved in PEG300/propylene glycol/H2O (55: 
25:20). Minocycline hyclate and doxycycline hyclate (Sigma-Aldrich) 
were dissolved in water. Animals were weighed, and weight-corrected 
volumes of dosing solution (100 l per 25 g) were administered by 
oral gavage or intraperitoneal injection of tylosin A. Experimentors 
involved in dosing were blinded to the treatment group except for 
L. sigmodontis studies.
Molecular assays
For synchronous B. malayi infections, determination of Wolbachia 
single copy wsp gene quantity was undertaken by qPCR, as previ-
ously described (11). In rodent screens where mature adult worm age 
varied, wsp quantity per worm was normalized to filarial nematode gst 
using Brugia- or Onchocerca-specific primers (11). Between 5 and 20 
individual worms were assayed, derived from dose groups of between 
three and nine animals. Experiments using L. sigmodontis quantified 
Wolbachia ftsZ and used L. sigmodontis actin for normalization, as 
previously described (27).
Testing bacterial susceptibility
Broth microdilution test methods were conducted according to 
the Clinical Laboratory Standards Institute guidelines (28) to deter-
mine the susceptibility of different bacterial strains to the tylosin 
A analogs and comparators. Concurrent quality control testing was 
performed to ensure proper test conditions and procedures. The 
quality control strains included Escherichia coli ATCC 25922, 
Staphylococcus aureus ATCC 29213, and Streptococcus pneumoniae 
ATCC 49619. All quality control results were within published 
ranges (29).
Testing L. loa in vitro
L. loa microfilariae were extracted from baboon peripheral blood and 
placed in culture in vitro, as previously described (30). Between 20 
and 30 microfilariae per well were seeded onto a 96-well plate con-
taining test compounds prepared in DMSO to a final concentration of 
1% in culture medium (10% FBS–supplemented Dulbecco’s modified 
Eagle’s medium). All compounds were tested in triplicate, and daily 
motility was scored as follows: 0 (immotile/dead), 1 (very slow, only tip 
movement), 2 (break in activity, sluggish), or 3 (fully motile, continu-
ously active) on day 2 compared to a DMSO-only control. Operators 
were blinded to treatment groups. Ethical and administrative clear-
ances for the use of baboons in this study were obtained from the 
Ministry of Scientific Research and Innovation of Cameroon (Re-
search permit no. 028/MIN-RESI/B00/C00/C10/C12) and Research 
Foundation for Tropical Diseases and the Environment (REFOTDE) 
Institutional Animal Ethics Committee (no. 2009/032). The animal pro-
cedures were conducted in accord ance with the guidelines of the Ani-
mal Care and Use Committee at the National Institutes of Health (USA) 
and University of Georgia, Athens, USA, as previously described (31).
Plasma drug concentrations in mice and gerbils
Oral drug doses were administered by gavage to BALB/c mice (Charles 
River Laboratories, USA) or Mongolian gerbils (Charles River Labora-
tories, Beijing). Serial blood samples collected into EDTA anticoagu-
lant for plasma concentration analysis were obtained from each animal 
after dosing. EDTA preserved plasma samples were extracted by 
protein precipitation with acetonitrile fortified with internal stan-
dards. The supernatant was injected into a high-performance liquid 
chromatography–mass spectroscopy (MS)/MS system for separa-
tion and quantitation. Detection was accomplished using a triple- 
quadruple mass spectrometer operated either in electrospray or in 
an atmospheric chemical ionization mode. The area under the plas-
ma concentration time curve (AUC) was calculated using the linear 
trapezoidal rule.
Statistical analysis
Percentage reduction in Wolbachia in microfilariae after in vivo drug 
treatments was normalized to median vehicle control concentrations 
derived from the same experimental infection and screen. Where 
repeat experimental data were available, data were pooled after nor-
malization. Grouped continuous variables were tested for normal 
distribution by D’Agostino-Pearson omnibus normality tests. Contin-
uous variables failing normal distribution tests were log10-transformed 
and retested. Continuous variables satisfying the assumptions of nor-
mal distribution were examined by one-way ANOVA with Dunnett’s 
multiple tests post hoc. Variables not satisfying the assumption of nor-
mality were compared by Mann-Whitney (two variables) or Kruskal- 
Wallis test with Dunnett’s multiple tests post hoc (>2 variables). Post 
hoc testing scrutinized inferior, noninferior, or superior anti-Wolbachia 
activity compared with doxycycline or minocycline controls or as-
sessed changes in microfilarial loads compared with vehicle controls 
or doxycyline/minocycline controls. Significance levels are indicated 
as *P < 0.05, ** P < 0.01, ***P < 0.001, and ****P < 0.0001. All statistics 
were undertaken using GraphPad Prism v.6 software.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/11/483/eaau2086/DC1
Fig. S1. Efficacy of tylosin A in Litomosoides larval model after intraperitoneal or oral 
dosing.
Fig. S2. Study design schematics for B. malayi, L. sigmodontis, and O. ochengi efficacy models.
Fig. S3. Preclinical PK/PD model of TylAMac analogs.
Fig. S4. In vitro counter screening against L. loa microfilariae.
Table S1. PK parameters of tylosin A after intraperitoneal and oral dosing in BALB/c mice.
Table S2. B. malayi larval worm burdens 2 weeks after dosing with doxycycline, tylosin A, 
A-1535469, or A-1574083 in IL-4R−/− BALB/c mice.
Table S3. Spectrum of TylAMac analogs and tylosin A against selected bacteria.
Table S4. B. malayi adult worm burdens 6 weeks after dosing with minocycline, tylosin A, or 
A-1535469 in CCR3−/− BALB/c mice.
Table S5. B. malayi adult worm burdens 6 weeks after dosing with doxycycline or A-1574083 in 
gerbils.
Table S6. L. sigmodontis adult worm burdens 16 weeks after dosing with doxycycline or 
A-1574083 in gerbils.
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Table S7. O. ochengi male worm burdens 6 weeks after dosing with minocycline, A-1535469, or 
A-1574083 in SCID mice.
Table S8. O. ochengi male worm burdens 6 weeks after dosing with doxycycline or A-1574083 
in gerbils.
Table S9. B. malayi adult worm burdens 24 weeks after dosing with doxycycline or A-1535469 
in SCID mice.
Data file S1. Source data for figures.
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nematodes in animal models of lymphatic filariasis and onchocerciasis. The authors showed that the tylosin A 
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